None listed
Conditions
Brief summary
We hypothesize that Blastx accelerates wound closure rates faster than Aquacel Ag Extra Plus on chronic burn wounds with better scarring outcomes. To test this theory, we will recruit patients with >4-week-old burn injuries and place them on an arm of the study, Comparing results and outcomes with the aid of AI technology and POSAS scores
Interventions
Patients with burn in juries >4 weeks old will be allocated into 2 arms of the study. The trial arm will be having 3mm thick blastx wound gel applied directly to the burn wound by burns nurses in clinic. This will htne be covered with a non-adherent pad. Patients will have Blastx applied to the burn twice a week with wound measurement occurring via photography with AI intelligence.. This will continue until wound closure.
Sponsors
Concord Hospital
Study design
Allocation
Randomised controlled trial
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
patient aged 18 years and over, burns that are >4 weeks old, burns managed by Burns team and burns that involve <1% Total body surface area (TBSA).
Exclusion criteria
patients aged 17 years and under, burns under 4 weeks old, burns sustained to specific anatomical locations, patients unable to perform informed consent or are receiving telehealth care.
Outcome results
None listed